Bioasis Technologies Inc. BIOAF
Set alert
0.00 USD 0.00 0.00%
At close · Oct 30
0.0001 Day range 0.0001
0.0001 52-week range 0.0002
- YTD
- -50.00%
- 1 year
- -50.00%
- Open
- 0.0001
- Prev close
- 0.0001
- Mkt cap
- 7.94K
- Vol
- 72.94K
- Avg vol
- 2.93K
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 0.0001
- High
- 0.0001
2Y chart
Signals (14)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | May 1, 2026 | 6 months ago |
| RSI: Oversold | Apr 13, 2026 | 6 months ago |
| MACD: Sell Signal | Jul 21, 2025 | 1 year ago |
| SMA: Bullish | Jul 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 2, 2025 | 1 year ago |
| RSI: Oversold | May 12, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 19, 2025 | 1 year ago |
| SMA: Bullish | Feb 27, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 27, 2025 | 1 year ago |
| RSI: Overbought | Feb 27, 2025 | 1 year ago |
| SMA: Bearish | Feb 4, 2025 | 1 year ago |
| RSI: Oversold | Feb 4, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 27, 2025 | 1 year ago |
| RSI: Overbought | Jan 3, 2025 | 1 year ago |
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 19, 2023 | Nov 1, 2022 | -0.01 | -0.01 | 0.00 | 0.00% |
| Oct 28, 2022 | Aug 1, 2022 | 0.00 | -0.01 | — | — |
News
- Financial Analysis: Prelude Therapeutics (NASDAQ:PRLD) versus Bioasis Technologies (OTCMKTS:BIOAF)
- Bioasis to Attend Upcoming Industry Conferences
- Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor
- Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³™ Fusion Protein Comprising Iduronate-2-sulfatase
- Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A
- Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager
- Bioasis Technologies reports positive results from an efficacy study of its blood-brain barrier penetrant
- Bioasis Announces Positive Results From an Efficacy Study of xB3™-IL-1RA in a Model of Multiple Sclerosis
- Bioasis Technologies appoints former PricewaterhouseCoopers veteran Dave Jenkins as CFO
- Bioasis Announces the Appointment of Dave Jenkins as Chief Financial Officer
Your note
Sign in to keep a note on BIOAF — it syncs with the Stock Master app.